BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $178
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $178.
BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $178.